Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Part of paid clinical trials in Irvine, California.
- Sponsor
- Lyell Immunopharma, Inc.
- Study ID
- NCT05826535
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
- Large B-cell Lymphoma
- Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Relapsed Non-Hodgkin Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Rondecabtagene autoleucel (ronde-cel) — DRUGCAR T-cell therapy
- Fludarabine — DRUGConditioning chemotherapy
- Cyclophosphamide — DRUGConditioning chemotherapy
Study Details
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.
Key Dates
- Start date
- May 9, 2023
- Status verified
- Apr 2026
- Primary completion
- Dec 31, 2028
- Completion
- Jun 30, 2031
Study Design
- Enrollment
- 270 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Ph1, 3rd or later line, 3L+ have not received prior CAR T (Cohort 1)
- Experimental: Ph1 CAR T experienced, 3L+ received at least two or more prior lines of treatment (Cohort 2)
- Experimental: Ph1, 2L Refractory/relapse within 1 year of 1st-line therapy & no prior CAR T (Cohort 3)
- Experimental: Ph1 (T-cell engager experienced, 3L+) received at least 2 prior lines including 1 TCE (Cohort 4)
- Experimental: Ph1 high risk 1st line, PET-positive after 2-3 cycles chemoimmunotherapy, no prior CAR T (Cohort 5)
- Experimental: Ph2, 3rd or later line, have not received prior CAR T (Cohort 1)Single dose determined during Phase 1.
Primary Outcome Measure
Phase 1: Evaluate the safety and tolerability of a single dose of ronde-cel administered as a single agent [ Time Frame: Baseline to Month 24 ]
Central Contacts
- Stephen Simko, MD000-000-0000
Locations (32)
Find similar trials in Irvine, CA
By research site
University of California-Irvine Medical Center· Irvine, CACedars-Sinai Medical Center· Los Angeles, CAUniversity of California, Los Angeles (UCLA) Medical Center· Los Angeles, CAScripps Clinic· San Diego, CAColorado Blood Cancer Institute· Denver, COMedstar Georgetown University Hospital· Washington D.C., DC
Related Studies
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)Recruiting · Center for International Blood and Marrow Transplant Research · Birmingham, Alabama
- Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)PHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas
- Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHLPHASE2 · Recruiting · New York Medical College · Valhalla, New York
- Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid TumorsPHASE1 · Recruiting · University of Wisconsin, Madison · Madison, Wisconsin